The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for commercialisation.
Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker ...
The FloStent™ System Promises to Redefine the BPH Care PathwayParis, France, and Milwaukee, WI, US, May 13, 2026 (GLOBE ...
Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s): A Pivotal, Randomized, Sham-Controlled Trial of the Urocross Expander System for Treatment of LUTS due to BPH – 30 Month Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results